Alternative Data for Vir Biotechnology
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 9 | Sign up | Sign up | Sign up |
| Sentiment | 82 | Sign up | Sign up | Sign up |
| Webpage traffic | 15,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 9 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,800 | Sign up | Sign up | Sign up |
| X Followers | 3,446 | Sign up | Sign up | Sign up |
| X Mentions | 94 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 33 | Sign up | Sign up | Sign up |
| Linkedin Employees | 479 | Sign up | Sign up | Sign up |
About Vir Biotechnology
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
| Price | $8.77 |
| Target Price | Sign up |
| Volume | 1,714,436 |
| Market Cap | $1.48B |
| Year Range | $4.79 - $11.09 |
| Dividend Yield | 0% |
| Analyst Rating | 67% buy |
| Industry | Biotechnology |
In the news
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million SharesMay 17 - Yahoo Entertainment |
|
Sotrovimab (Xevudy: Vir Biotechnology, GlaxoSmithKline) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMay 11 - GlobeNewswire |
|
 |
Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?April 26 - Yahoo Entertainment |
Vir Biotechnology (VIR) Posts 80.98% Year-To-Date GrowthApril 22 - Yahoo Entertainment |
|
Vir Biotechnology (VIR) Leading with Its BiTEs TherapyApril 10 - Yahoo Entertainment |
|
Vir Biotechnology Commences $200M Common Stock OfferingFebruary 24 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '26 | -29,000 | 2.8M | -2.8M | -126M | -130M | -0.850 |
| Q4 '25 | 64M | -367M | 431M | -43M | -40M | -0.310 |
| Q3 '25 | 240,000 | 151M | -151M | -163M | -160M | -1.170 |
| Q2 '25 | 1.2M | 98M | -96M | -111M | -116M | -0.800 |
| Q1 '25 | 3M | 118M | -115M | -121M | -136M | -0.880 |
Insider Transactions View All
| SATO VICKI L filed to sell 1,078,391 shares at $10. May 4 '26 |
| De Backer Marianne filed to sell 948,145 shares at $9.2. April 7 '26 |
| SATO VICKI L filed to sell 1,100,391 shares at $9.1. April 2 '26 |
| Sabatini Brent filed to sell 61,902 shares at $9.1. March 24 '26 |
| SATO VICKI L filed to sell 1,122,391 shares at $10. March 3 '26 |
Similar companies
Read more about Vir Biotechnology (VIR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Vir Biotechnology
The Market Cap of Vir Biotechnology is $1.48B.
Currently, the price of one share of Vir Biotechnology stock is $8.77.
The VIR stock price chart above provides a comprehensive visual representation of Vir Biotechnology's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Vir Biotechnology shares. Our platform offers an up-to-date VIR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Vir Biotechnology (VIR) does not offer dividends to its shareholders. Investors interested in Vir Biotechnology should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Vir Biotechnology are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
